Buprenorphine and Rifapentine: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Buprenorphine
Rifapentine
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Rifapentine can weaken how well buprenorphine works for you. Rifapentine speeds up the liver enzyme (called CYP3A4) that breaks down buprenorphine. That means your body clears the buprenorphine faster, so the level in your blood drops. If you take buprenorphine for pain or for opioid use disorder, you might notice it not working as well, or you may feel withdrawal symptoms like restlessness, chills, sweating, stomach upset, or aches.
The good news is your care team can manage this. Please keep taking both medicines as prescribed, and let your pharmacist or doctor know so they can adjust your dose and watch you more closely.
Effect: Rifapentine (a potent CYP3A4 inducer) increases buprenorphine metabolism, lowering buprenorphine plasma concentrations and reducing efficacy. Risk of opioid withdrawal.
- Mechanism: Induction of CYP3A4-mediated buprenorphine metabolism (buprenorphine is active drug, not a prodrug, so induction reduces effect).
- Severity/evidence: Major; probable. Onset unspecified (induction typically develops over days to weeks).
- Management: If rifapentine is needed, titrate buprenorphine upward to stable effect and monitor for withdrawal. On rifapentine discontinuation, reduce buprenorphine dose and monitor for respiratory depression. For long-acting subQ formulations, ensure adequate levels; consider a formulation allowing precise dose adjustment.
What happens
Reduced buprenorphine exposure and reduced efficacy of buprenorphine
Interaction Deep Dive
Because a CYP3A4 inducer can lower buprenorphine plasma levels, taking the two together may bring on symptoms of opioid withdrawal. When a patient on buprenorphine must begin a CYP3A4 inducer, one option is to raise the buprenorphine dose until steady drug effects are reached, while watching for withdrawal. Conversely, if the CYP3A4 inducer is stopped in a patient being treated with buprenorphine, consider lowering the buprenorphine dose and observe for respiratory depression2. Should dose adjustment be impossible once the CYP3A4 inducer is removed, move the patient back to a buprenorphine formulation that allows finer dose titration. For patients switched from transmucosal buprenorphine given alongside CYP3A4 inducers, confirm through monitoring that subQ buprenorphine yields an adequate plasma buprenorphine concentration. For those already receiving subQ buprenorphine who then need a CYP3A4 inducer, watch for withdrawal. When the buprenorphine dose is insufficient in the presence of the concomitant drug, and that drug can neither be reduced nor stopped, modify the buprenorphine dose. If the available doses will not reach the target dose, use a buprenorphine formulation that allows more precise dose adjustments1.
Why it happens (mechanism)
Induction of CYP3A4-mediated metabolism of buprenorphine
How to manage this interaction
Keep taking both medicines as prescribed unless your care team tells you otherwise. This combination is manageable with a few steps.
- Your team may increase your buprenorphine dose while you are on rifapentine, and adjust it back down when rifapentine is stopped, so watch for withdrawal (aches, chills, sweating) or, later, oversedation.
- If you use a long-acting injectable buprenorphine, your team may monitor more closely or switch you to a form (like film or tablet) that allows finer dose adjustments.
- Tell your pharmacist or prescriber about both medicines and report any withdrawal or reduced pain relief.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) The impact of a concurrently administered CYP3A4 inducer on buprenorphine exposure in patients receiving subQ buprenorphine has not been investigated; nevertheless, these interactions have been demonstrated in studies employing transmucosal buprenorphine. Buprenorphine's effects may vary according to the route of administration 1.
Common questions
Can I take Buprenorphine and Rifapentine together?
Rifapentine can lower buprenorphine levels and trigger withdrawal or reduced effect; keep taking both as prescribed and ask your care team about adjusting your buprenorphine dose and monitoring you more closely. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Buprenorphine and Rifapentine interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Buprenorphine and Rifapentine interaction managed?
Keep taking both medicines as prescribed unless your care team tells you otherwise. This combination is manageable with a few steps. Your team may increase your buprenorphine dose while you are on rifapentine, and adjust it back down when rifapentine is stopped, so watch for withdrawal (aches, chills, sweating) or, later, oversedation. If you use a long-acting injectable buprenorphine, your team m… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Buprenorphine or Rifapentine need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (2)
- Product Information: BRIXADI(TM) subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection. Braeburn Inc (per FDA), Plymouth Meeting, PA, 2023. DailyMed
- Product Information: ZUBSOLV(R) sublingual tablets, buprenorphine naloxone sublingual tablets. Orexo US Inc (per FDA), Morristown, NJ, 2023. DailyMed
Keep reading about Buprenorphine
Keep reading about Rifapentine
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist